MINNEAPOLIS, April 08, 2016 -- On March 3, 2016, Vascular Solutions, Inc., (Nasdaq:VASC) initiated a nationwide recall of Guardian II hemostasis valves used in catheterization procedures. Specific lots of the products have been recalled because they pose an increased risk of air leakage that may lead to an air embolism, which could result in serious injury or death. This recall only affects the Guardian II hemostasis valves and does not include the Guardian II NC hemostasis valves. No injuries have been reported in association with this issue to date.
Healthcare facilities that have the affected Guardian II hemostasis valves should remove the products from their inventory and return them to Vascular Solutions.
The recalled products were manufactured from March 2015 to February 2016 and distributed from April 2015 to February 2016.
The recalled products are specific lots of Model Numbers 8210 and 8211. A listing of the recalled lots is available from Vascular Solutions and has been provided to each facility that purchased the affected products. A total of 26,550 devices have been manufactured, with 5,283 distributed in the United States. The condition that led to the recall may affect approximately 2.4% of recalled devices.
Vascular Solutions Inc. voluntarily initiated the recall on March 3, 2016 through an Urgent Medical Device Recall notification distributed to purchasers of the affected products. The notification identified the specific lots subject to the recall and included instructions on how to return the affected products.
The U.S. Food and Drug Administration (FDA) classified this as a Class I recall. FDA defines Class I recalls as “a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death.”
Consumers with questions may contact the company by phone at 1-888-240-6001 Monday through Friday, between the hours of 8:00 a.m. and 5:00 p.m. Central Time or by email at [email protected]. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program:
- Online at http://www.fda.gov/medwatch/report.htm
(form available to fax (1-800-FDA-0178) or mail), or - Call FDA 1-800-FDA-1088 to request a reporting form
About Vascular Solutions
Vascular Solutions, Inc. is an innovative medical device company that focuses on developing unique clinical solutions for coronary and peripheral vascular procedures. The company’s product line consists of more than 90 products and services that are sold to interventional cardiologists, interventional radiologists, electrophysiologists, and vein specialists through its direct U.S. sales force and international independent distributor network.
For further information, connect to www.vasc.com.
Contact: Phil Nalbone VP of Corporate Development Vascular Solutions, Inc. (763) 656-4371


Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 



